Immutep Limited (IMMP)
| Market Cap | 321.71M |
| Revenue (ttm) | 11.38M |
| Net Income (ttm) | -9.29M |
| Shares Out | 74.82M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,699 |
| Open | 4.26 |
| Previous Close | 4.30 |
| Day's Range | 4.22 - 4.45 |
| 52-Week Range | 1.65 - 7.95 |
| Beta | 1.46 |
| Analysts | Buy |
| Price Target | 6.50 (+48.7%) |
| Est. Earnings Date | n/a |
About IMMP
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-smal...
Financial Performance
In 2020, Immutep's revenue was 16.50 million, an increase of 120.31% compared to the previous year's 7.49 million. Losses were -13.47 million, -26.58% less than in 2019.
Financial numbers in millions AUDFinancial StatementsAnalyst Forecast
According to 2 analysts, the average rating for Immutep stock is "Buy." The 12-month stock price forecast is 6.50, which is an increase of 48.74% from the latest price.
News
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
SYDNEY, AUSTRALIA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatme...
Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021
SYDNEY, Australia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 1 September 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 re...
Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to advise its Chinese partner for eftilagi...
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201...
Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cance...
Immutep Shares Are Trading Higher On Green Signal To Start Efti Combo Trial In First-Line Head & Neck Cancer
Immutep Limited (NASDAQ: IMMP) has completed all the necessary steps with the FDA and has received institutional review board approval to commence its Phase 2b TACTI-003 trials in the U.S. Patient recru...
Immutep To Initiate Efti Triple Combination Therapy Trial In Solid Tumors, Launches $60M Placement
Immutep (NASDAQ: IMMP) will begin a Phase 1 trial to evaluate its lead product candidate, eftilagimod alpha (efti or IMP321), in conjunction with chemotherapy and anti-PD-1 therapy. The trial, named INS...
7 Reddit Penny Stocks to Buy if You Have $100 to Spare
Reddit penny stocks are full of risk and reward, which is why $100 won't hurt you, but it can reward you handsomely. The post 7 Reddit Penny Stocks to Buy if You Have $100 to Spare appeared first on Inv...
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
SYDNEY, AUSTRALIA, June 04, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatmen...
Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pat...
SYDNEY, AUSTRALIA, June 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer ...
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT-005 trial in patients with solid tumors. The tri...
Immutep To Present At The Jefferies Virtual Healthcare Conference
SYDNEY, AUSTRALIA, May 25, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer an...
Immutep Stock Gains on Encouraging Data from Early-Stage Solid Cancer Studies
Immutep Limited (NASDAQ: IMMP) has announced that data from its TACTI-002 and INSIGHT-004 studies have been published in abstracts for the American Society of Clinical Oncology's 2021 Annual Meeting. Da...
Top Penny Stocks to Buy Now? 4 Big Movers to Watch Today
Are these the top penny stocks to buy in 2021? Take a look and decide for yourself The post Top Penny Stocks to Buy Now?
7 Reddit Penny Stocks Promising to Cure Cancer
These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...
Immutep Operational Update
Sydney, AUSTRALIA, May 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatment...
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual...
SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer an...
Immutep Receives A$1,155,055 R&D Tax Incentive
SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from t...
Why Immutep Limited Stock Popped Today
Investors liked the company's latest regulatory update.
VERY Stock: Is a VERY Big Mix-Up Causing Vericity to Skyrocket?
Vericity (VERY) stock is on the rise Thursday morning despite a lack of news for the company in what could be a mix-up for investors. The post VERY Stock: Is a VERY Big Mix-Up Causing Vericity to Skyroc...
What's Going On With APRE Stock And IMMP Stock Today?
Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia....
IMMP Stock: The Big Patent News Boosting Immutep Today
IMMP stock is getting a boost in Thursday trading after European regulators gave one of its cancer antibodies a key patent. The post IMMP Stock: The Big Patent News Boosting Immutep Today appeared first...
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metast...
Sydney, AUSTRALIA, April 08, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer...
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer,...